Concepts (276)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Gastrointestinal Hemorrhage | 31 | 2024 | 229 | 14.550 |
Why?
|
| Colonoscopy | 14 | 2023 | 264 | 4.760 |
Why?
|
| Anticoagulants | 11 | 2022 | 408 | 3.810 |
Why?
|
| Hospitalization | 11 | 2022 | 849 | 3.190 |
Why?
|
| Patient Discharge | 7 | 2024 | 300 | 2.230 |
Why?
|
| Hemostasis, Endoscopic | 3 | 2018 | 15 | 1.940 |
Why?
|
| Esophageal Diseases | 3 | 2015 | 26 | 1.590 |
Why?
|
| Warfarin | 3 | 2020 | 103 | 1.470 |
Why?
|
| Risk Assessment | 8 | 2019 | 2262 | 1.210 |
Why?
|
| Colonic Polyps | 4 | 2023 | 126 | 1.190 |
Why?
|
| Liver Cirrhosis | 4 | 2018 | 297 | 1.150 |
Why?
|
| Esophageal Neoplasms | 4 | 2018 | 321 | 1.140 |
Why?
|
| Fibrinolytic Agents | 2 | 2018 | 202 | 1.110 |
Why?
|
| Humans | 62 | 2024 | 86645 | 1.080 |
Why?
|
| Esophageal Stenosis | 2 | 2015 | 26 | 1.060 |
Why?
|
| Eosinophilic Esophagitis | 2 | 2015 | 18 | 1.050 |
Why?
|
| Endoscopy, Digestive System | 2 | 2015 | 65 | 1.040 |
Why?
|
| Patient Readmission | 3 | 2019 | 329 | 1.040 |
Why?
|
| Liver Diseases | 2 | 2017 | 238 | 1.020 |
Why?
|
| Colorectal Neoplasms | 4 | 2022 | 938 | 0.990 |
Why?
|
| Physicians, Family | 1 | 2024 | 40 | 0.960 |
Why?
|
| Emergency Service, Hospital | 5 | 2024 | 484 | 0.960 |
Why?
|
| Proton Pump Inhibitors | 2 | 2022 | 31 | 0.950 |
Why?
|
| Juniperus | 1 | 2023 | 1 | 0.940 |
Why?
|
| Endoscopy | 4 | 2019 | 332 | 0.910 |
Why?
|
| Polyps | 1 | 2023 | 28 | 0.910 |
Why?
|
| Middle Aged | 31 | 2021 | 25028 | 0.880 |
Why?
|
| Aged | 26 | 2021 | 18415 | 0.880 |
Why?
|
| Inflammatory Bowel Diseases | 3 | 2020 | 549 | 0.860 |
Why?
|
| Practice Guidelines as Topic | 2 | 2021 | 1036 | 0.850 |
Why?
|
| Propensity Score | 3 | 2021 | 136 | 0.850 |
Why?
|
| Text Messaging | 1 | 2022 | 27 | 0.820 |
Why?
|
| Radiology | 1 | 2024 | 194 | 0.800 |
Why?
|
| Retrospective Studies | 16 | 2024 | 8491 | 0.800 |
Why?
|
| Endoscopy, Gastrointestinal | 2 | 2019 | 153 | 0.800 |
Why?
|
| Early Diagnosis | 2 | 2018 | 131 | 0.800 |
Why?
|
| Blood Coagulation Factors | 1 | 2021 | 20 | 0.780 |
Why?
|
| Blood Transfusion | 2 | 2018 | 157 | 0.780 |
Why?
|
| Vitamin K | 1 | 2021 | 25 | 0.770 |
Why?
|
| Barrett Esophagus | 3 | 2018 | 93 | 0.770 |
Why?
|
| Acute Coronary Syndrome | 1 | 2021 | 45 | 0.750 |
Why?
|
| Risk Adjustment | 1 | 2020 | 39 | 0.740 |
Why?
|
| Recurrence | 7 | 2018 | 1139 | 0.740 |
Why?
|
| Patient Admission | 2 | 2018 | 112 | 0.740 |
Why?
|
| Machine Learning | 2 | 2019 | 232 | 0.730 |
Why?
|
| Thromboembolism | 2 | 2018 | 119 | 0.730 |
Why?
|
| Angiodysplasia | 1 | 2019 | 4 | 0.720 |
Why?
|
| Platelet Aggregation Inhibitors | 1 | 2021 | 134 | 0.720 |
Why?
|
| Spiders | 1 | 2019 | 14 | 0.710 |
Why?
|
| Critical Pathways | 1 | 2019 | 35 | 0.710 |
Why?
|
| Gastrointestinal Agents | 2 | 2022 | 161 | 0.700 |
Why?
|
| Blood Coagulation Disorders | 1 | 2020 | 63 | 0.700 |
Why?
|
| Diverticulum, Colon | 1 | 2018 | 10 | 0.670 |
Why?
|
| Male | 29 | 2021 | 40967 | 0.660 |
Why?
|
| Diverticulum | 1 | 2019 | 44 | 0.660 |
Why?
|
| Severity of Illness Index | 5 | 2019 | 1801 | 0.640 |
Why?
|
| Female | 29 | 2021 | 44534 | 0.630 |
Why?
|
| Acute Disease | 4 | 2022 | 826 | 0.630 |
Why?
|
| Gastroenterology | 2 | 2017 | 134 | 0.620 |
Why?
|
| Time Factors | 5 | 2018 | 5210 | 0.620 |
Why?
|
| Venous Thromboembolism | 1 | 2020 | 153 | 0.610 |
Why?
|
| Cost-Benefit Analysis | 3 | 2016 | 454 | 0.610 |
Why?
|
| Hepatitis, Autoimmune | 1 | 2017 | 19 | 0.600 |
Why?
|
| Atrial Fibrillation | 1 | 2020 | 288 | 0.580 |
Why?
|
| Aged, 80 and over | 12 | 2019 | 6509 | 0.580 |
Why?
|
| Alanine Transaminase | 1 | 2016 | 73 | 0.580 |
Why?
|
| Aspartate Aminotransferases | 1 | 2016 | 73 | 0.580 |
Why?
|
| Colonic Diseases | 1 | 2017 | 65 | 0.580 |
Why?
|
| Fellowships and Scholarships | 2 | 2017 | 108 | 0.580 |
Why?
|
| Risk Factors | 8 | 2019 | 5417 | 0.580 |
Why?
|
| Gastroenterologists | 1 | 2017 | 30 | 0.570 |
Why?
|
| Patient Care Management | 1 | 2016 | 31 | 0.570 |
Why?
|
| Stomach Diseases | 1 | 2015 | 19 | 0.540 |
Why?
|
| Non-alcoholic Fatty Liver Disease | 2 | 2016 | 212 | 0.530 |
Why?
|
| Adenocarcinoma in Situ | 1 | 2015 | 4 | 0.530 |
Why?
|
| Decision Support Techniques | 1 | 2017 | 160 | 0.520 |
Why?
|
| Pneumonia, Viral | 1 | 2020 | 316 | 0.520 |
Why?
|
| Coronavirus Infections | 1 | 2020 | 301 | 0.520 |
Why?
|
| Cryosurgery | 1 | 2015 | 41 | 0.520 |
Why?
|
| Accidental Falls | 1 | 2015 | 50 | 0.510 |
Why?
|
| Cohort Studies | 6 | 2020 | 2767 | 0.510 |
Why?
|
| Withholding Treatment | 2 | 2014 | 112 | 0.510 |
Why?
|
| Antibodies, Monoclonal, Humanized | 1 | 2020 | 930 | 0.500 |
Why?
|
| Intestinal Diseases | 1 | 2015 | 79 | 0.500 |
Why?
|
| Hospital Mortality | 1 | 2017 | 349 | 0.500 |
Why?
|
| Psychotropic Drugs | 1 | 2015 | 75 | 0.490 |
Why?
|
| Physicians, Primary Care | 1 | 2016 | 104 | 0.490 |
Why?
|
| Multivariate Analysis | 5 | 2020 | 999 | 0.480 |
Why?
|
| Salvage Therapy | 1 | 2015 | 233 | 0.470 |
Why?
|
| Adult | 18 | 2021 | 25648 | 0.470 |
Why?
|
| Stomach Neoplasms | 1 | 2016 | 266 | 0.460 |
Why?
|
| Coronary Artery Disease | 1 | 2018 | 350 | 0.460 |
Why?
|
| Ischemic Attack, Transient | 1 | 2014 | 181 | 0.450 |
Why?
|
| Prospective Studies | 10 | 2021 | 4213 | 0.450 |
Why?
|
| Education, Medical, Graduate | 1 | 2017 | 369 | 0.450 |
Why?
|
| Wounds and Injuries | 1 | 2015 | 231 | 0.420 |
Why?
|
| Prognosis | 6 | 2018 | 3680 | 0.420 |
Why?
|
| Esophagoscopy | 3 | 2018 | 87 | 0.420 |
Why?
|
| Pulmonary Embolism | 1 | 2014 | 222 | 0.410 |
Why?
|
| Venous Thrombosis | 1 | 2014 | 243 | 0.410 |
Why?
|
| Adenocarcinoma | 2 | 2018 | 1169 | 0.400 |
Why?
|
| Follow-Up Studies | 4 | 2024 | 3640 | 0.380 |
Why?
|
| Logistic Models | 3 | 2020 | 1187 | 0.380 |
Why?
|
| Databases, Factual | 3 | 2019 | 814 | 0.380 |
Why?
|
| Glottis | 1 | 2010 | 11 | 0.370 |
Why?
|
| Vocal Cords | 1 | 2010 | 25 | 0.370 |
Why?
|
| Carcinoma in Situ | 1 | 2010 | 53 | 0.350 |
Why?
|
| Diagnosis, Computer-Assisted | 2 | 2023 | 332 | 0.350 |
Why?
|
| Laryngeal Neoplasms | 1 | 2010 | 89 | 0.350 |
Why?
|
| Catheter Ablation | 3 | 2016 | 233 | 0.340 |
Why?
|
| Young Adult | 6 | 2020 | 5976 | 0.320 |
Why?
|
| Dabigatran | 2 | 2020 | 24 | 0.320 |
Why?
|
| Treatment Outcome | 6 | 2021 | 7993 | 0.320 |
Why?
|
| Administration, Oral | 2 | 2020 | 684 | 0.310 |
Why?
|
| Chickenpox | 1 | 2007 | 39 | 0.310 |
Why?
|
| Molecular Epidemiology | 1 | 2007 | 53 | 0.300 |
Why?
|
| Herpesvirus 3, Human | 1 | 2007 | 43 | 0.300 |
Why?
|
| Cryotherapy | 2 | 2018 | 29 | 0.300 |
Why?
|
| Herpes Zoster | 1 | 2007 | 78 | 0.300 |
Why?
|
| United States | 7 | 2024 | 6674 | 0.300 |
Why?
|
| Adolescent | 7 | 2021 | 8982 | 0.290 |
Why?
|
| Liver | 3 | 2016 | 1230 | 0.290 |
Why?
|
| Inpatients | 2 | 2022 | 297 | 0.280 |
Why?
|
| Ceruloplasmin | 2 | 2015 | 9 | 0.270 |
Why?
|
| Hepatolenticular Degeneration | 2 | 2015 | 19 | 0.270 |
Why?
|
| Stroke | 1 | 2014 | 965 | 0.270 |
Why?
|
| Elasticity Imaging Techniques | 2 | 2016 | 59 | 0.260 |
Why?
|
| Length of Stay | 2 | 2018 | 703 | 0.260 |
Why?
|
| Proportional Hazards Models | 3 | 2018 | 859 | 0.260 |
Why?
|
| Decision Support Systems, Clinical | 2 | 2015 | 103 | 0.250 |
Why?
|
| Canada | 1 | 2024 | 204 | 0.240 |
Why?
|
| Catheters | 1 | 2024 | 74 | 0.230 |
Why?
|
| Radiography, Dual-Energy Scanned Projection | 1 | 2023 | 17 | 0.230 |
Why?
|
| Computers | 1 | 2023 | 112 | 0.230 |
Why?
|
| Angiography | 1 | 2024 | 208 | 0.230 |
Why?
|
| Tomography, X-Ray Computed | 2 | 2024 | 2601 | 0.230 |
Why?
|
| Aftercare | 1 | 2024 | 85 | 0.230 |
Why?
|
| Crohn Disease | 2 | 2021 | 730 | 0.220 |
Why?
|
| Carcinoma, Squamous Cell | 1 | 2010 | 1076 | 0.220 |
Why?
|
| Histamine H2 Antagonists | 1 | 2022 | 15 | 0.220 |
Why?
|
| Algorithms | 2 | 2023 | 1830 | 0.210 |
Why?
|
| Cathartics | 1 | 2022 | 27 | 0.210 |
Why?
|
| Remission Induction | 2 | 2021 | 722 | 0.210 |
Why?
|
| Adenoma | 2 | 2021 | 235 | 0.200 |
Why?
|
| Musculoskeletal Pain | 1 | 2021 | 10 | 0.200 |
Why?
|
| Capsule Endoscopy | 1 | 2021 | 33 | 0.200 |
Why?
|
| Ticlopidine | 1 | 2021 | 25 | 0.200 |
Why?
|
| Aspirin | 2 | 2022 | 156 | 0.200 |
Why?
|
| Infant | 4 | 2018 | 3047 | 0.190 |
Why?
|
| Clinical Competence | 2 | 2017 | 751 | 0.190 |
Why?
|
| Ontario | 1 | 2020 | 52 | 0.190 |
Why?
|
| Child, Preschool | 4 | 2018 | 3613 | 0.190 |
Why?
|
| Chemoprevention | 1 | 2020 | 91 | 0.180 |
Why?
|
| Artificial Intelligence | 2 | 2021 | 298 | 0.180 |
Why?
|
| Blood Coagulation | 1 | 2020 | 91 | 0.180 |
Why?
|
| Risk | 2 | 2018 | 674 | 0.180 |
Why?
|
| Randomized Controlled Trials as Topic | 2 | 2021 | 865 | 0.170 |
Why?
|
| Incidence | 3 | 2018 | 1577 | 0.170 |
Why?
|
| Mortality | 1 | 2020 | 149 | 0.170 |
Why?
|
| Chronic Pain | 1 | 2021 | 145 | 0.170 |
Why?
|
| Biological Products | 1 | 2021 | 143 | 0.170 |
Why?
|
| Triage | 1 | 2019 | 108 | 0.170 |
Why?
|
| Data Warehousing | 1 | 2018 | 3 | 0.170 |
Why?
|
| Lower Gastrointestinal Tract | 1 | 2018 | 8 | 0.170 |
Why?
|
| Delayed Diagnosis | 1 | 2018 | 29 | 0.160 |
Why?
|
| Age Factors | 3 | 2018 | 1851 | 0.160 |
Why?
|
| Patient Protection and Affordable Care Act | 1 | 2019 | 66 | 0.160 |
Why?
|
| Area Under Curve | 1 | 2018 | 334 | 0.160 |
Why?
|
| Hepatic Encephalopathy | 1 | 2018 | 40 | 0.160 |
Why?
|
| Data Mining | 1 | 2018 | 42 | 0.160 |
Why?
|
| Early Detection of Cancer | 1 | 2022 | 394 | 0.160 |
Why?
|
| Quality Improvement | 1 | 2022 | 428 | 0.160 |
Why?
|
| Drug Therapy | 1 | 2018 | 70 | 0.160 |
Why?
|
| Nitrogen | 1 | 2018 | 70 | 0.160 |
Why?
|
| Secondary Prevention | 1 | 2018 | 162 | 0.150 |
Why?
|
| Betacoronavirus | 1 | 2020 | 258 | 0.150 |
Why?
|
| Comorbidity | 2 | 2018 | 943 | 0.150 |
Why?
|
| Predictive Value of Tests | 2 | 2018 | 1673 | 0.150 |
Why?
|
| Models, Educational | 1 | 2017 | 50 | 0.150 |
Why?
|
| Decision Making, Computer-Assisted | 1 | 2016 | 12 | 0.150 |
Why?
|
| Fecal Impaction | 1 | 2016 | 3 | 0.150 |
Why?
|
| Disease Progression | 2 | 2018 | 1531 | 0.140 |
Why?
|
| Liver Function Tests | 1 | 2016 | 93 | 0.140 |
Why?
|
| Gastroscopy | 1 | 2016 | 23 | 0.140 |
Why?
|
| Hospital Charges | 1 | 2016 | 29 | 0.140 |
Why?
|
| Emergencies | 1 | 2017 | 113 | 0.140 |
Why?
|
| Odds Ratio | 1 | 2018 | 678 | 0.140 |
Why?
|
| Drug Administration Schedule | 1 | 2018 | 916 | 0.140 |
Why?
|
| Program Development | 1 | 2017 | 124 | 0.140 |
Why?
|
| Mentors | 1 | 2017 | 76 | 0.140 |
Why?
|
| Pyridines | 1 | 2018 | 310 | 0.140 |
Why?
|
| Child | 4 | 2018 | 6928 | 0.140 |
Why?
|
| Medicare | 2 | 2016 | 410 | 0.140 |
Why?
|
| Hepatitis | 1 | 2015 | 35 | 0.130 |
Why?
|
| Program Evaluation | 1 | 2017 | 297 | 0.130 |
Why?
|
| Medical Order Entry Systems | 1 | 2015 | 25 | 0.130 |
Why?
|
| Medical Overuse | 1 | 2015 | 36 | 0.130 |
Why?
|
| beta-Alanine | 1 | 2014 | 6 | 0.130 |
Why?
|
| Unnecessary Procedures | 1 | 2015 | 51 | 0.130 |
Why?
|
| Rivaroxaban | 1 | 2014 | 12 | 0.130 |
Why?
|
| Colonic Pouches | 1 | 2015 | 67 | 0.130 |
Why?
|
| Enoxaparin | 1 | 2014 | 23 | 0.130 |
Why?
|
| Benzodiazepines | 1 | 2015 | 65 | 0.130 |
Why?
|
| Thiophenes | 1 | 2014 | 48 | 0.130 |
Why?
|
| Morpholines | 1 | 2014 | 65 | 0.130 |
Why?
|
| Nucleosides | 1 | 2014 | 22 | 0.130 |
Why?
|
| Food | 1 | 2015 | 86 | 0.130 |
Why?
|
| Pyridones | 1 | 2014 | 51 | 0.130 |
Why?
|
| Constipation | 1 | 2015 | 63 | 0.120 |
Why?
|
| Treatment Failure | 1 | 2015 | 285 | 0.120 |
Why?
|
| Eosinophils | 1 | 2015 | 194 | 0.120 |
Why?
|
| Population Surveillance | 1 | 2015 | 219 | 0.120 |
Why?
|
| ROC Curve | 1 | 2017 | 752 | 0.120 |
Why?
|
| Hepatitis B, Chronic | 1 | 2014 | 32 | 0.120 |
Why?
|
| Hospital Costs | 1 | 2015 | 105 | 0.120 |
Why?
|
| Cost of Illness | 1 | 2015 | 150 | 0.120 |
Why?
|
| Pandemics | 1 | 2020 | 740 | 0.120 |
Why?
|
| Nucleotides | 1 | 2014 | 95 | 0.120 |
Why?
|
| Heparin | 1 | 2014 | 175 | 0.120 |
Why?
|
| Anesthesia | 1 | 2016 | 164 | 0.120 |
Why?
|
| Pyrazoles | 1 | 2014 | 153 | 0.120 |
Why?
|
| Guideline Adherence | 1 | 2015 | 223 | 0.120 |
Why?
|
| Benzimidazoles | 1 | 2014 | 140 | 0.120 |
Why?
|
| Ischemia | 1 | 2015 | 243 | 0.120 |
Why?
|
| Referral and Consultation | 1 | 2016 | 328 | 0.110 |
Why?
|
| Curriculum | 1 | 2017 | 539 | 0.110 |
Why?
|
| Health Knowledge, Attitudes, Practice | 1 | 2017 | 508 | 0.110 |
Why?
|
| Diagnostic Imaging | 1 | 2016 | 469 | 0.110 |
Why?
|
| Sensitivity and Specificity | 1 | 2017 | 1991 | 0.110 |
Why?
|
| Computer Simulation | 1 | 2016 | 1078 | 0.100 |
Why?
|
| Attitude of Health Personnel | 1 | 2017 | 636 | 0.100 |
Why?
|
| Longitudinal Studies | 1 | 2014 | 1019 | 0.100 |
Why?
|
| Mass Screening | 1 | 2015 | 618 | 0.100 |
Why?
|
| Colitis, Ulcerative | 1 | 2018 | 711 | 0.100 |
Why?
|
| Antiviral Agents | 1 | 2014 | 510 | 0.090 |
Why?
|
| Reproducibility of Results | 1 | 2017 | 2705 | 0.090 |
Why?
|
| Dose-Response Relationship, Radiation | 1 | 2010 | 188 | 0.090 |
Why?
|
| Prevalence | 2 | 2018 | 1239 | 0.090 |
Why?
|
| London | 1 | 2007 | 16 | 0.080 |
Why?
|
| Chickenpox Vaccine | 1 | 2007 | 7 | 0.080 |
Why?
|
| Deoxyribonucleases, Type II Site-Specific | 1 | 2007 | 30 | 0.080 |
Why?
|
| DNA, Viral | 1 | 2007 | 265 | 0.070 |
Why?
|
| Survival Rate | 1 | 2010 | 1863 | 0.070 |
Why?
|
| Polymerase Chain Reaction | 1 | 2007 | 927 | 0.070 |
Why?
|
| Neoplasm Staging | 1 | 2010 | 1939 | 0.060 |
Why?
|
| Neoplasm Recurrence, Local | 1 | 2010 | 1313 | 0.060 |
Why?
|
| Iodine | 1 | 2023 | 43 | 0.060 |
Why?
|
| Genotype | 1 | 2007 | 1851 | 0.050 |
Why?
|
| Observational Studies as Topic | 1 | 2022 | 48 | 0.050 |
Why?
|
| Network Meta-Analysis | 1 | 2021 | 7 | 0.050 |
Why?
|
| Infant, Newborn | 1 | 2007 | 2379 | 0.050 |
Why?
|
| Single-Blind Method | 1 | 2021 | 153 | 0.050 |
Why?
|
| Leukocyte L1 Antigen Complex | 1 | 2021 | 39 | 0.050 |
Why?
|
| Intestine, Small | 1 | 2023 | 303 | 0.050 |
Why?
|
| Ustekinumab | 1 | 2021 | 47 | 0.050 |
Why?
|
| Infliximab | 1 | 2021 | 151 | 0.050 |
Why?
|
| Anti-Inflammatory Agents, Non-Steroidal | 1 | 2022 | 243 | 0.050 |
Why?
|
| Animals | 1 | 2019 | 26582 | 0.050 |
Why?
|
| Polymorphism, Single Nucleotide | 1 | 2007 | 2357 | 0.040 |
Why?
|
| Sex Distribution | 1 | 2018 | 173 | 0.040 |
Why?
|
| Age Distribution | 1 | 2018 | 204 | 0.040 |
Why?
|
| Veterans | 1 | 2018 | 72 | 0.040 |
Why?
|
| Vibration | 1 | 2015 | 49 | 0.030 |
Why?
|
| Hepatitis B e Antigens | 1 | 2014 | 8 | 0.030 |
Why?
|
| Quality-Adjusted Life Years | 1 | 2015 | 138 | 0.030 |
Why?
|
| Lamivudine | 1 | 2014 | 13 | 0.030 |
Why?
|
| Tenofovir | 1 | 2014 | 7 | 0.030 |
Why?
|
| International Classification of Diseases | 1 | 2015 | 69 | 0.030 |
Why?
|
| Guidelines as Topic | 1 | 2016 | 162 | 0.030 |
Why?
|
| Organophosphonates | 1 | 2014 | 50 | 0.030 |
Why?
|
| Regression Analysis | 1 | 2016 | 596 | 0.030 |
Why?
|
| Survival Analysis | 1 | 2018 | 1538 | 0.030 |
Why?
|
| Adenine | 1 | 2014 | 85 | 0.030 |
Why?
|
| Guanine | 1 | 2014 | 208 | 0.030 |
Why?
|
| Academic Medical Centers | 1 | 2016 | 379 | 0.030 |
Why?
|
| Biopsy | 1 | 2015 | 1163 | 0.030 |
Why?
|